175 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF 130. Tellor KB, Wang M, Green MS, Armbruster AL. Evaluation of apixaban for the treatment of nonvalvular atrial fibrillation with regard to dosing and safety in a community hospital. J Pharm Technol. 2017;33(4):140–5. 131. Yagi N, Suzuki S, Arita T, Otsuka T, Semba H, Kano H, et al. Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Heart Vessels. 2020;35(1):110–7. 132. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–90. 8
RkJQdWJsaXNoZXIy MTk4NDMw